IMAGEENS Raises 1.2Mn€ Seed Financing Round to Launch Its First Two Products
15.4.2021 12:41:00 EEST | Business Wire | Press release
IMAGEENS, a Paris-based medical Artificial Intelligence (AI) startup developing software solutions for the analysis of medical images, has secured 1.2Mn€ in seed financing. The round was led by Anaxago, with a participation from BADGE (Business Angels des Grandes Ecoles), COALESCENCE, and existing IMAGEENS investors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210415005466/en/
IMAGEENS' software solutions allow radiologists, cardiologists and vascular surgeons to make personalized decisions and to better assess the cardiovascular risk of their patients, thanks to highly accurate medical imaging data.
The funding will allow IMAGEENS to accelerate the development and commercialization of ArtFun+, an artificial intelligence software and its prognostic biomarkers for cardiovascular imaging, and LABEL, an algorithmic solution for the automatic classification and valorization of medical imaging data. It will also allow to strengthen its team with key R&D talents and build its commercial team to scale the deployment of its software solutions.
"We are delighted to have been able to quickly complete this round table in collaboration with ANAXAGO. We will be able to announce the launch of several strategic projects as well as key hires in the coming months, which will be the cornerstones of IMAGEENS' development over the next few years," said Robert Baldwin, CEO of IMAGEENS.
ArtFun+ stems from the US National Institute of Health (NIH)-funded Multi-Ethnic Study of Atherosclerosis (MESA) which studied the prognostic power of imaging biomarkers on a multi-ethnic cohort of 3675 patients across the United States. In the study, the imaging biomarkers of ArtFun+ were shown to be highly predictive of death and hard cardiovascular for patients between 45 and 84 years old. Beyond the MESA trial, the imaging biomarkers of ArtFun+ were studied in 77 scientific publications and used in 31 leading clinical centers around the globe.
Today, IMAGEENS is in the process of obtaining FDA and CE-clearance for ArtFun+ in routine cardiovascular care to complement to cardiac MRI exams with cardiovascular risk biomarkers enabling improved follow-up and surgical decisions in ischemic cardiopathies, acute coronary syndrome, and aortic aneurysms.
Since late 2020, IMAGEENS has also developed a complementary business to its diagnostic solutions, by helping Europe’s largest medical data warehouses improve the quality of their medical data and use it for R&D and AI-training purposes. By working with leading medical institutions such as the AP-HP in Paris, IMAGEENS has developed a comprehensive set of image classification algorithms that automatically create metadata allowing the data warehouses to get a detailed understanding of the databases’ content, and the ability to precisely query the medical data to setup cohorts for R&D and AI-training projects.
ABOUT IMAGEENS
Founded in 2017, IMAGEENS develops software solutions for doctors to leverage the full potential of advanced medical imaging data. IMAGEENS commercializes two products: ArtFun+, an innovative software to calculate vascular stiffness and flow imaging biomarkers that are predictive of patients’ long-term risk of death and hard cardiovascular events, and LABEL, a set of image classification algorithms that enable large medical data warehouses to precisely query and create data cohorts for R&D and AI-training projects.
ABOUT ANAXAGO
Created in 2012, the Anaxago group is the first 100% digital private neo-bank, accessible to the greatest number of people, combining impact and performance. With more than 100,000 members, 250 companies and real estate projects financed since its creation and more than 250 million euros collected, Anaxago stands out for the selectivity and the support of the investment projects proposed on its platform. Anaxago is an independent group, majority owned by its founders, and currently has 40 employees. The investment in IMAGEENS was led by Alex Heraud and Gaston Vasseur. Anaxago counsels: M Guilain Hippolyte, Reed Smith LLP.
www.anaxago.com
ABOUT BADGE
Created in 2004 Les Business Angels des Grandes Ecoles is one of the largest networks of Business Angels in France. The mission is to support the development of emerging innovative projects with high growth potential. Since 2005 BADGE has financed 188 projects with 38 M€, having generated a total financing of more than 100 M€.
www.business-angels.info
ABOUT COALESCENCE
Coalescence is a network of Business Angels sharing the same values; they wish to promote the growth of young innovative projects. Beyond finance the members of Coalescence bring kind support with their various professional background.
www.coalescence.fr
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210415005466/en/
Contact information
Press Contact:
IMAGEENS: press@imageens.com
Website: www.imageens.com
Anaxago: gaston@anaxago.com
Press Agency:
Annie-Florence Loyer
afloyer@newcap.fr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Bolivarian Republic of Venezuela Announces the Initiation of a Comprehensive Public Debt Restructuring Process13.5.2026 23:08:00 EEST | Press release
The Bolivarian Republic of Venezuela announces today its decision to initiate a comprehensive restructuring of its external public debt obligations. CONTEXT & RATIONALE Over the past decade, Venezuela's economy has been severely impacted by external shocks – from the end of the commodity super-cycle to foreign sanctions and COVID-19 – resulting in a sharp economic contraction, a protracted default since 2017, and a ballooning of public sector liabilities. The country nonetheless possesses a strong economic potential, including unique hydrocarbon and mineral endowments. A recovery is underway, and Venezuela is committed to accelerating it through a comprehensive reform agenda in support of growth, fiscal sustainability, monetary stabilization, and enhanced governance. Restoring public debt sustainability is central to this agenda: the current debt overhang constrains external financing, limits public investment capacity, and prevents full re-engagement with the international financial s
Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise13.5.2026 22:00:00 EEST | Press release
Boomi, the data activation company for AI, today announced it has signed a letter of intent to acquire Lunar.dev, an innovator in AI and MCP gateway. The proposed acquisition is expected to enrich the Boomi Enterprise Platform and Boomi Connect with advanced capabilities to govern and scale AI usage across enterprise systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513850557/en/ Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise As organizations move from AI experimentation to production, controlling how agents and AI applications interact with LLMs at scale has become critical. Lunar.dev addresses this need with an AI gateway that delivers granular, policy-driven control over AI interactions, with the visibility, security, and performance required for enterprise environments. These capabilities enable organizations to move from pilot to production with confiden
BeOne Medicines’ BEQALZI ™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma13.5.2026 20:27:00 EEST | Press release
BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™(bee-KAHL-zee; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. BEQALZI was designed to enhance BCL2 inhibition—with greater potency, selectivity, and a pharmacologic profile with potential to improve efficacy, tolerability, and convenience over others in the class. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513542161/en/ BeOne Medicines' flagship U.S. biologics manufacturing and clinical R&D facility at the Princeton West Innovation Campus in Hopewell, N.J. Michael Wang, M.D., Global Principal Investigator
Boomi Unveils Innovations That Power the Agentic Enterprise13.5.2026 17:30:00 EEST | Press release
Boomi, the data activation company for AI, today announced a major expansion of the Boomi Enterprise Platform at Boomi World 2026, introducing new capabilities across orchestrated agentic workflows, agentic engineering, governed agent connectivity, grounded agent context, and localized agent infrastructure. Together, these innovations are designed to power the agentic enterprise — where agents and humans work together to drive action and operationalize AI at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513996223/en/ Boomi Unveils Innovations That Power the Agentic Enterprise The enterprise has reached a defining moment as AI becomes the primary interface for work and MCP emerges as the new standard. While the shift toward a headless, agentic enterprise is inevitable, this vision is colliding with skyrocketing cloud costs and trapped data. For many, layering agents onto a fragmented landscape only magnifies govern
Boomi and Couchbase Partner to Power Enterprise AI Agents with Trusted Recollection, Connectivity, and Governance13.5.2026 17:30:00 EEST | Press release
Boomi, the data activation company for AI, and Couchbase, Inc., the operational data platform for AI, today announced a partnership through which the two companies are collaborating closely to accelerate AI pilots to production. The companies will co-engineer solutions that give customers a production-ready foundation for agentic AI, combining Boomi's connectivity, runtime, and governance for AI agents with Couchbase's scalable recollection and vector capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513350337/en/ Enterprises deploying AI agents today face a common challenge: while agents perform well in pilots, they struggle to scale due to inconsistent access to trusted context, recollection, and real-time business data. Lack of governance, auditability, and operational control drives up compute costs while diminishing productivity and revenue. “2026 is the year organizations move from AI experimentation to a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom